Pregabalin Capsule
Product Images NDC 68788-7521

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-7521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Caps 50mg 30s Count

Pregabalin Capsules 50 mg oral capsules label showing the product name and strength prominently on a yellow background. The label states it is a generic for Lyrica and includes manufacturer information for ScieGen Pharmaceuticals, Inc. It displays storage instructions and a caution about drug transfer. The label features dosage directions in English and Spanish, a barcode, and the labeler Preferred Pharmaceuticals, Inc.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. Four lines represent different groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph illustrates comparative effectiveness in pain improvement.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line chart comparing the percent improvement in pain from baseline between Pregabalin 100 mg taken three times a day and placebo. The y-axis shows the percent of patients improved, while the x-axis shows the percent improvement in pain from baseline. Two lines indicate patient improvement trends for both treatment and placebo groups.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at dosages of 75 mg, 150 mg, and 300 mg taken two times a day against a placebo, showing trends of pain improvement across the groups.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating their respective effectiveness in pain improvement over a range from 0 to 100 percent.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating the proportion of patients experiencing various levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph comparing the responder rates (%) for different doses of Pregabalin versus placebo in two studies labeled Study E1 and Study E3. The x-axis shows dose levels including placebo and varying daily doses of Pregabalin, while the y-axis quantifies responder rate percentages from 0% to 60%. A note indicates statistically significant differences versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response chart illustrating median percent seizure reduction from baseline versus dose in mg/day. The graph presents data points for four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID, with significance levels (p-values) indicated at various doses up to 600 mg/day. Placebo is noted as the control dose.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. The Pregabalin 800 mg line trends highest, indicating greater patient improvement relative to placebo and lower doses. Vertical lines mark thresholds at 30% and 50% improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR (likely a clinical event) over 180 days. The graph compares two groups: Pregabalin (solid line) and placebo (dashed line). The y-axis represents the percentage of subjects without LTR, starting at 0% up to 100%, and the x-axis represents the duration in days from 0 to 180.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to week 12 between Pregabalin and placebo groups. The x-axis shows the percent improved from baseline to week 12 BOCF, while the y-axis shows the percent of subjects improved, with Pregabalin demonstrating consistently higher improvement than placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over time from baseline to week 16 using the BOCF method. Two lines represent Pregabalin and Placebo showing the percentage of subjects improved at various time points, with Pregabalin generally showing higher improvement percentages than Placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) using age, weight, and serum creatinine levels, with a multiplication factor of 0.85 for female patients. The formula is presented as a text-based equation.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin showing its molecular framework including an amino group, carboxyl group, and specific carbon chain arrangement as depicted in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.